Table 2.
Scintigraphic findings after 13-CRA therapy in 53 patients with radioiodine non-avid NMTC metastases
| WBS after redifferentiation therapy | Last pre redifferentiation WBS | |||
| No uptake | Uptake in thyroid bed | |||
| No scintigraphic response in metastases | 35* | (66%) | 8 | (15%) |
| Scintigraphic response in metastases | 8 | (15%) | 1 | (2%) |
| Lung | 5 | (9%) | 0 | (0%) |
| Mediastinum | 1 | (2%) | 1 | (2%) |
| Lung and lymph node | 1 | (2%) | 0 | (0%) |
| Lung and bone | 1 | (2%) | 0 | (0%) |
| Persistent thyroid bed uptake in pre- and post-13-CRA RDT rxWBS | 0 | (0%) | 1 | (2%) |
13-CRA, 13-cis-retinoic acid; RDT, re-differentiation therapy;
rxWBS, post-therapy whole-body scintigraphy
* in one patient there was only diagnostic WBC for comparison